Anesthetic Effect – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Anesthetic Effect – Pipeline Review, H2 2017’, provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect

The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects

The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anesthetic Effect

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co Ltd

Lee's Pharmaceutical Holdings Ltd

Lipicard Technologies Ltd

Paion AG

Phosphagenics Ltd

Physica Pharma

Primex Pharmaceuticals Oy

Proteus SA

Recro Pharma Inc

Taiwan Liposome Company Ltd

The Medicines Company

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anesthetic Effect - Overview

Anesthetic Effect - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anesthetic Effect - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anesthetic Effect - Companies Involved in Therapeutics Development

4P Therapeutics LLC

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co Ltd

Lee's Pharmaceutical Holdings Ltd

Lipicard Technologies Ltd

Paion AG

Phosphagenics Ltd

Physica Pharma

Primex Pharmaceuticals Oy

Proteus SA

Recro Pharma Inc

Taiwan Liposome Company Ltd

The Medicines Company

Anesthetic Effect - Drug Profiles

alphaxalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carboetomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-09 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Flexicaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabafol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSK-3486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Carboetomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Etomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midazolam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neosaxitoxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-5109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHY-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Anesthetic Effect - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anesthetic Effect - Dormant Projects

Anesthetic Effect - Discontinued Products

Anesthetic Effect - Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial

Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy

Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015

Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients

Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia

Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy

Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States

Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Anesthetic Effect, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Anesthetic Effect – Pipeline by 4P Therapeutics LLC, H2 2017

Anesthetic Effect – Pipeline by Biolab Farmaceutica Ltda, H2 2017

Anesthetic Effect – Pipeline by Crescita Therapeutics Inc, H2 2017

Anesthetic Effect – Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017

Anesthetic Effect – Pipeline by Expanesthetics Inc, H2 2017

Anesthetic Effect – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Anesthetic Effect – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Anesthetic Effect – Pipeline by Lipicard Technologies Ltd, H2 2017

Anesthetic Effect – Pipeline by Paion AG, H2 2017

Anesthetic Effect – Pipeline by Phosphagenics Ltd, H2 2017

Anesthetic Effect – Pipeline by Physica Pharma, H2 2017

Anesthetic Effect – Pipeline by Primex Pharmaceuticals Oy, H2 2017

Anesthetic Effect – Pipeline by Proteus SA, H2 2017

Anesthetic Effect – Pipeline by Recro Pharma Inc, H2 2017

Anesthetic Effect – Pipeline by Taiwan Liposome Company Ltd, H2 2017

Anesthetic Effect – Pipeline by The Medicines Company, H2 2017

Anesthetic Effect – Dormant Projects, H2 2017

Anesthetic Effect – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Anesthetic Effect, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports